UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?

被引：1
作者：
Ibrahim, Rebecca [1 ]
Khoury, Rita [1 ]
Ibrahim, Tony [1 ]
Le Cesne, Axel
Assi, Tarek [1 ,2 ]
机构：
[1] Gustave Roussy Canc Campus, Div Int Patients Care, Villejuif, France
[2] 114 Rue Edouard Vaillant, Villejuif, France
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 196卷
关键词：
Breast cancer; Genetic; Neutropenia; Triple negative; SACITUZUMAB GOVITECAN; COLORECTAL-CANCER; IRINOTECAN CPT-11; OPEN-LABEL; TOXICITY; GENOTYPE; GENE; POLYMORPHISMS; CHEMOTHERAPY; BILIRUBIN;
D O I：
10.1016/j.critrevonc.2024.104265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an important component for the metabolism and glucoronidation of certain drugs, including irinotecan and sacituzumab govitecan (SG); therefore, various UGT1A1 polymorphisms leading to decreased function of the UGT1A1 enzyme may lead to increased risk of treatment-related side effects. Testing for UGT1A1 polymorphism is not routinely adopted in clinical practice; that is due to the lack of concise studies and recommendations concerning the clinical relevance of this test and its impact on the quality of life of cancer patients. The knowledge regarding UGT1A1 polymorphism and its clinical relevance will be reviewed in this article, as well as the published literature on the association between UGT1A1 polymorphism and the toxicity risk of irinotecan as well as sacituzumab govitecan. The current recommendations and guidelines on UGT1A1 testing will be discussed in detail in the hopes of providing guidance to oncologists in their clinical practice.
引用
收藏
页数：8
相关论文
共 73 条
  • [1] Trop-2 Is a Determinant of Breast Cancer Survival
    Ambrogi, Federico
    Fornili, Marco
    Boracchi, Patrizia
    Trerotola, Marco
    Relli, Valeria
    Simeone, Pasquale
    La Sorda, Rossana
    Lattanzio, Rossano
    Querzoli, Patrizia
    Pedriali, Massimo
    Piantelli, Mauro
    Biganzoli, Elia
    Alberti, Saverio
    [J]. PLOS ONE, 2014, 9 (05):
  • [2] Ando Y, 2000, CANCER RES, V60, P6921
  • [3] [Anonymous], Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, DOI [10.1056/NEJMoa2028485, DOI 10.1056/NEJMOA2028485]
  • [4] [Anonymous], Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer, DOI [10.1056/NEJMoa2115022, DOI 10.1056/NEJMOA2115022]
  • [5] [Anonymous], Cancer of the Breast (Female) - Cancer Stat Facts
  • [6] [Anonymous], Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer, DOI [10.1056/NEJMoa2112431?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%200pubmed, DOI 10.1056/NEJMOA2112431?URL_VER=Z39.88-2003&RFR_ID=ORI:RID:CROSSREF.ORG&RFR_DAT=CR_PUB0PUBMED]
  • [7] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [8] Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype
    Baek, Grace
    Jung, Lindsey
    Duong, Arianne
    Gralow, Julie
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (03) : 710 - 716
  • [9] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [10] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) : 1529 - 1541
12345678